{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:59:15Z","timestamp":1792213155969,"version":"4.4.0"},"reference-count":25,"publisher":"Baishideng Publishing Group Inc.","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastroenterol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n                  <jats:p>Helicobacter pylori  (H. pylori ) is a Gram-negative bacillus classified as a Group I carcinogen by the World Health Organization. However, the efficacy of eradication therapies has declined in recent years, primarily due to the increasing prevalence of antibiotic resistance. The Maastricht VI\/Florence Consensus Report highlights the importance of tailoring treatment strategies to local epidemiological data and individual antimicrobial susceptibility patterns.<\/jats:p>\n                  <jats:p>AIM<\/jats:p>\n                  <jats:p>To investigate the efficacy of precision-guided first-line therapy for H. pylori  infection using genotypic antibiotic susceptibility testing (G-AST).<\/jats:p>\n                  <jats:p>METHODS<\/jats:p>\n                  <jats:p>This single-center randomized controlled trial enrolled 194 H. pylori -positive patients at a tertiary hospital in Qingdao, China (October 2022-August 2024). Participants were randomized to receive either a 14-day bismuth quadruple therapy (BQT: Amoxicillin, clarithromycin, esomeprazole, and bismuth) or a 14-day G-AST-guided regimen with tailored antibiotics (clarithromycin, levofloxacin, or tetracycline). Treatment efficacy and adverse events were compared between groups using intention-to-treat (ITT) and per-protocol (PP) analyses. Primary and secondary outcomes were analyzed with \u03c7\u00b2  tests.<\/jats:p>\n                  <jats:p>RESULTS<\/jats:p>\n                  <jats:p>Of 194 patients enrolled, 180 (92.8%) completed the study as planned. In the ITT analysis, the eradication rate was higher in the G-AST group than in the BQT group [92.8% (95%CI: 85.8-96.5) vs  79.4% (95%CI: 70.3-86.2), P  = 0.007], with a risk difference of 13.4% (95%CI: 3.7-23.2). In the PP analysis, eradication rates were 97.8% (95%CI: 92.4-99.4) in the G-AST group and 84.1% (95%CI: 75.1-90.3) in the BQT group (P  = 0.001), with a risk difference of 13.7% (95%CI: 5.5-23.0). Adverse event incidence did not differ significantly between groups (30.9% vs  28.9%, P  = 0.754).<\/jats:p>\n                  <jats:p>CONCLUSION<\/jats:p>\n                  <jats:p>G-AST-guided therapy yielded higher eradication rates than empirical BQT in first-line H. pylori  treatment without increasing adverse events, supporting the clinical utility of individualized, resistance-based therapy.<\/jats:p>","DOI":"10.3748\/wjg.v31.i42.110717","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:06:21Z","timestamp":1762995981000},"source":"Crossref","is-referenced-by-count":6,"title":["Precision therapy guided by genotypic antibiotic resistance for\n                    <i>Helicobacter pylori<\/i>\n                    eradication: A prospective, randomized controlled trial"],"prefix":"10.3748","volume":"31","author":[{"given":"Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Bin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.12.022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002546"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00431-8"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321372"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00097-3"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.635831"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2015.35.5.494"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S305996"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2021.106393"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13250"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13497"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30219-4"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107325"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00449-x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i18.2272"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00550-23"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12467"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01131-10"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18378"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S466975"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2015.05.003"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i22.3508"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13128"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318254ebdd"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v31\/i42\/110717.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v31\/i42\/110717.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:06:25Z","timestamp":1762995985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v31\/i42\/110717.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":25,"journal-issue":{"issue":"42"},"alternative-id":["110717"],"URL":"https:\/\/doi.org\/10.3748\/wjg.v31.i42.110717","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}